Not Yet RecruitingNot Applicable

Sclerotherapy and Candida Antigen in Treatment of Common Warts

Egypt75 participantsStarted 2024-12-20

Plain-language summary

This study aims to evaluate the efficacy and safety of intralesional injections of candida antigen, polidocanol sclerotherapy and combined candida antigen with polidocanol in treatment of patients with common warts.

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age group: \>18years. * Confirmed diagnosis by clinical and dermoscopic examination of common wart will be made. Exclusion Criteria: * Patients who receive any treatment for wart in the last month before the study. * Patients with history of renal or liver disease. * Patients with any evidence of bleeding diathesis, vaso-occulusive or thrombo-embolic disorders. * Pregnant and lactating females. * Patients who receive immunosuppressive therapy. * Patients' refusal. * Patients with history or evidenced hypersensitivity to any component used in this study.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

size of warts

Timeframe: session every 2 weeks until complete clearance of warts or for a maximum of 6 treatment sessions and one month after last session

Trial details

NCT IDNCT06749665

SponsorSohag University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-01

Contact for this trial

Heba S Osman

01013846228 heba_shawky_post@med.sohag.edu.eg

View on ClinicalTrials.gov More Common Wart trials

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.